HighTide TherapeuticsHTTIF 14 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, HighTide Therapeutics ranks worse than 105820% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HighTide Therapeutics EBITDA Margin % Related Terms
HighTide Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HighTide Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HTTIF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, HighTide Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HighTide Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HighTide Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HighTide Therapeutics (HTTIF) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HighTide Therapeutics and its competitors. According to the industry distribution chart, HighTide Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is HighTide Therapeutics' EBITDA Margin % too high?
HighTide Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, HighTide Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places HighTide Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score
Get the complete analysis for HTTIF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTTIF has been successfully added to your 
